Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Evogene Ltd. EVGN
$0.67
+$0.03 (4.72%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
26190258.00000000
-
week52high
1.30
-
week52low
0.55
-
Revenue
1675000
-
P/E TTM
-1
-
Beta
0.83204800
-
EPS
-0.66000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мар 2023 г. в 14:00
Описание компании
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 08 окт 2021 г. | |
| Aegis Capital | Buy | 29 июл 2021 г. | |
| Cantor Fitzgerald | Overweight | 01 дек 2020 г. | |
| Credit Suisse | Outperform | Outperform | 12 ноя 2014 г. |
| Deutsche Bank | Buy | 17 дек 2013 г. | |
| Aegis Capital | Buy | Buy | 12 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Evogene Ltd. (EVGN) Q4 2022 Earnings Call Transcript
Seeking Alpha
10 мар 2023 г. в 00:11
Evogene Ltd. (NASDAQ:EVGN ) Q4 2022 Earnings Conference Call March 9, 2023 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Eyal Ronen - Executive Vice President, Business Development Yaron Eldad - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brett Reiss - Janney Montgomery Scott Brian Wright - ROTH Capital Operator Ladies and gentlemen, thank you for standing by.
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 09:53
Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Evogene Subsidiary Casterra Ag: Castor Seeds Benefiting From Changes In EU Laws
Seeking Alpha
21 февр 2023 г. в 23:06
Evogene's subsidiary Casterra has developed proprietary genomically modified, high-yield & high oil-content Castor seed varieties. In September 2022 the EU banned palm oil and soybean as a biofuel or biodiesel feedstock beginning 2023 through to 2030. Castor oil is a replacement.
All You Need to Know About Evogene (EVGN) Rating Upgrade to Strong Buy
Zacks Investment Research
18 янв 2023 г. в 13:33
Evogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Evogene Ltd. (EVGN) Q3 2022 Earnings Call Transcript
Seeking Alpha
17 ноя 2022 г. в 14:32
Start Time: 09:00 January 1, 0000 9:34 AM ET Evogene Ltd. (NASDAQ:EVGN ) Q3 2022 Earnings Conference Call November 17, 2022, 09:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by.